Category: AbbVie

Beam Therapeutics Stock: A Leader in Gene Editing Tech?

Don’t invest in stories. Don’t invest in a company before they have meaningful revenues. Don’t invest in drug developers that have a great deal of regulatory risk. These are all rules we need to break if we want exposure to a technology that allows mankind to start playing with the…

Continue Reading Beam Therapeutics Stock: A Leader in Gene Editing Tech?

Roche (RHHBY) Gets EC Approval for Polivy Combination in DLBCL – May 26, 2022

Roche (RHHBY Quick QuoteRHHBY – Free Report) recently announced that the European Commission (“EC”) has granted approval to lymphoma drug Polivy (polatuzumab vedotin) in combination with MabThera (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Polivy is…

Continue Reading Roche (RHHBY) Gets EC Approval for Polivy Combination in DLBCL – May 26, 2022